Gilead Makes Exclusive Deal With CVS for Hepatitis C Drugs

Gilead Sciences Inc. agreed to make its hepatitis C medicines the exclusive treatments for CVS Health Corp. customers, intensifying a drug-industry rivalry to win patients for the $1,000-a-day medicines.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.